Below is a summary of our committee structure and membership information. To read more about any of the committees, click on committee names in the chart below.
| |
Audit
|
Compensation
|
Governance and Nominating
|
Stephen C. McCluski  
|
|
|
|
Former Senior Vice President and Chief Financial Officer, Bausch & Lomb
Stephen C. McCluski has been a director of ImmunoGen since April 2007, and the Chairman of the Board since November 2009. Mr. McCluski served as Senior Vice President and Chief Financial Officer of Bausch & Lomb Incorporated, a manufacturer of health care products for the eye, from 1995 to his retirement in 2007. Prior to that he served in various executive capacities at Bausch & Lomb and its subsidiaries from 1989 to 1995. Mr. McCluski is also a director of the James P. Wilmot Cancer Center of the University of Rochester and of Standard Microsystems Corporation.
|
|
Mark Goldberg, M.D.
|
|
|
|
Senior Vice President of Product Development and Internal Advisor, Synageva BioPharma Corp.
Mark Goldberg, M.D., has been a director of ImmunoGen since November 2011. Dr. Goldberg has served as Senior Vice President of Product Development and Internal Advisor for Synageva BioPharma Corp., a biopharmaceutical company, since September 2011. Prior to that he served in various management capacities of increasing responsibility at Genzyme Corporation, a biopharmaceutical company, from 1996 to 2011, most recently as Senior Vice President, Clinical Research and Global Therapeutic Head, Oncology, Genetic Health, and as Chairman of Genzyme's Early Product Review Board. Prior to joining Genzyme, he was a full-time staff physician at Brigham and Women's Hospital and the Dana-Farber Institute, where he still holds appointments. Dr. Goldberg is an Associate Professor of Medicine at Harvard Medical School. Dr. Goldberg holds a Doctor of Medicine degree from Harvard Medical School. Dr. Goldberg is also a director of Synageva BioPharma Corp.
|
|
Dean Mitchell
|
|
|
|
President and CEO, Lux Biosciences, Inc
Dean Mitchell has been a director of ImmunoGen since January 2012. Mr. Mitchell is President and CEO of Lux Biosciences, Inc., and also a director on its board. He previously was President and CEO of Alpharma, Inc. and, before that, of Guilford Pharmaceuticals. Prior to joining Guilford in 2004, Mr. Mitchell held senior-level positions at Bristol-Myers Squibb, including President, International Pharmaceuticals and President, North America Primary Care. Prior to joining Bristol-Myers Squibb in 2001, Mr. Mitchell had a fourteen-year career with GlaxoSmithKline, Inc., becoming Senior Vice President, Clinical Development and Product Strategy in 2000. Mr. Mitchell is also a director of Intrexon Corporation and of Ista Pharmaceuticals.
|
|
Nicole Onetto, M.D.
|
|
|
|
Deputy Director, Ontario Institute for Cancer Research
Nicole Onetto, MD, has been a director of ImmunoGen since 2005. Dr. Onetto serves as Deputy Director of the Ontario Institute for Cancer Research. Prior to this, she served as Senior Vice President and Chief Medical Officer of ZymoGenetics, Inc., a biotechnology company specializing in protein therapeutics, from 2005 to 2009. She also served as Executive Vice President and Chief Medical Officer at OSI Pharmaceuticals, Inc., a biopharmaceutical company, from 2003 to 2005, and as Executive Vice President of OSI Pharmaceutical's Oncology business from 2002 to 2003. Prior to that she served as Senior Vice President, Medical Affairs, at Gilead Sciences, Inc., a biopharmaceutical company, from 2000 to 2001. Dr. Onetto has a Doctor of Medicine degree from the University of Paris V, France.
|
|
Kristine Peterson
|
|
|
|
CEO, Valeritas, Inc.
Kristine Peterson has been a director of ImmunoGen since January 2012. Ms. Peterson is CEO of Valeritas, Inc., and also a director on its board. She previously was Company Group Chairman, Biotech Business, at Johnson & Johnson, where she was responsible for research, development, manufacturing, and commercialization of oncology, immunology, and other biotechnology therapeutics for the company. Prior to joining J&J in 2004 as Executive VP, Pharmaceutical Group Strategic Marketing, Ms. Peterson had a twenty-year career with Bristol-Myers Squibb, rising through the organization to become Senior VP, Global Marketing before taking Senior VP and President roles at Biovail Corporation in 2003. Ms. Peterson is active in the Biotechnology Industry Organization (BIO) and also serves on the board of Amarin Corporation.
|
|
Howard Pien
|
|
|
|
Former Chairman of the Board and Chief Executive Officer of Medarex, Inc.
Mr. Pien has been a director of ImmunoGen since November 2009. He was the Chairman of the Board and Chief Executive Officer of Medarex, Inc. from 2007 to its acquisition by Bristol-Myers Squibb Company in September 2009. Prior to that, he was President and Chief Executive Officer of Chiron Corporation from 2003 to its acquisition by Novartis, and before that Mr. Pien held positions of increasing responsibility at GlaxoSmithKline and its predecessor, SmithKline Beecham, at Abbott Laboratories and at Merck & Co. He is also a director of ViroPharma Incorporated and Vanda Pharmaceuticals.
|
|
Mark Skaletsky
|
|
|
|
President and Chief Executive Officer, Fenway Pharmaceuticals
Mark Skaletsky has been a director of ImmunoGen since 2000. Mr. Skaletsky has served as Chairman of the Board and Chief Executive Officer of Fenway Pharmaceuticals, Inc., a drug development company, since April 2008. Prior to that he served as Chairman of the Board and Chief Executive Officer of Trine Pharmaceuticals, Inc. (formerly Essential Therapeutics, Inc.), a drug development company, from 2001 to 2007. Prior to that he served as Chairman of the Board and Chief Executive Officer of The Althexis Company, Inc. a drug discovery company, from 2000 to its acquisition by Essential Therapeutics in 2001. Mr. Skaletsky is also a director of Alkermes, Inc., AMAG Pharmaceuticals, Inc. and Targacept, Inc.
|
|
Joseph J. Villafranca, Ph.D.
|
|
|
|
Senior Vice President, Life Sciences, Business Development, Tunnell Consulting
Joseph J. Villafranca, Ph.D., has been a director of ImmunoGen since 2004. Dr. Villafranca has served as Senior Vice President – Operations and Principal & Practice Director, Life Sciences, of Tunnell Consulting, a consulting firm focusing on the life sciences industry, since 2006. Prior to that he served as President of Biopharmaceutical Consultants LLC from 2005 to 2006. Prior to that he served as Executive Vice President, Pharmaceutical Development and Operations at Neose Technologies, Inc., a biotechnology company, from 2002 to 2005. Prior to that he served in various executive positions at Bristol-Myers Squibb Company over a period of 11 years. Dr. Villafranca holds a Ph.D. in Biochemistry/Chemistry from Purdue University and completed his postdoctoral work at the Institute for Cancer Research in Philadelphia, Pennsylvania.
|
|
Richard J. Wallace
|
|
|
|
Former Senior Vice President of Research and Development at GlaxoSmithKline
Richard J. Wallace has been a director of ImmunoGen since November 2007. Mr. Wallace served as a Senior Vice President for Research and Development at GlaxoSmithKline plc (GSK), a pharmaceutical company, from 2004 to his retirement in 2008. Prior to that he served in various executive capacities for GSK and its predecessor companies and their subsidiaries from 1992 to 2004. Mr. Wallace's experience prior to joining GSK included eight years with Bristol-Myers Squibb Company and seven years at Johnson & Johnson (in assignments spanning marketing, sales, manufacturing and general management). Mr. Wallace is also a director of Clinical Data, Inc. and Bridgehead International Ltd.
|
Stock transaction information provided by EDGAR Online. ImmunoGen, Inc. makes no representation or warranty with respect to any of the information contained herein, takes no responsibility for supplementing, updating or correcting any such information and shall have no liability with respect to any such information. This listing does not include derivatives, such as stock option grants or shares purchased through an employee stock purchase plan. For recent transactions, including derivative transactions, see our Section 16 SEC filings page.
